Untitled case

I'll research this case and its lead consolidated action before drafting.

Let me dig into the specific consolidated member case, the docket, and the judge.

Case Overview & Background

Parties and their roles. This is a brand-versus-generic Hatch‑Waxman case, not an NPE/PAE or university assertion. Plaintiffs are Helsinn Healthcare S.A., a privately held, family-owned Swiss pharmaceutical group based in Lugano that in-licenses early-stage compounds, funds their development, holds the NDA and out-licenses commercial rights; and Roche Palo Alto LLC, the originator (via Syntex) of the 5‑HT₃ antagonist palonosetron, which licensed the molecule and related IP to Helsinn in 1998. Helsinn's U.S. commercialization partner is Eisai Inc., which obtained exclusive U.S./Canada marketing rights to Aloxi® through its 2008 acquisition of MGI Pharma and books U.S. sales (co-promoted with Helsinn Therapeutics (U.S.), Inc.). Defendants in this member case were the first-wave ANDA filers: [Dr. Reddy's Laboratories, Ltd.](/litigations/by-plaintiff/Dr.%20Reddy's%20Laboratories%2C%20Ltd.) and Dr. Reddy's Laboratories, Inc. (the U.S. subsidiary is a New Jersey corporation based in Bridgewater), Sandoz Inc., and Teva Pharmaceuticals USA, Inc. / Teva Pharmaceutical Industries, Ltd. Dr. Reddy's, Sandoz and Teva were the first ANDA sponsors to challenge Aloxi®'s Orange Book patents and therefore shared 180-day first-filer exclusivity.

Accused product and technology. The accused conduct is the filing of ANDAs under 35 U.S.C. § 271(e)(2)(A) seeking approval to market generic palonosetron hydrochloride injection — a branded Aloxi® copy — before expiration of Helsinn's Orange Book patents. Teva filed a single consolidated ANDA covering two strengths: 0.25 mg/5 mL (chemotherapy-induced nausea and vomiting, "CINV") and 0.075 mg/1.5 mL (post-operative nausea and vomiting, "PONV"), both at a 0.05 mg/mL palonosetron concentration. Helsinn's asserted claims all cover the 0.25 mg dose in a 5 mL, EDTA-containing, mannitol-buffered, room-temperature-stable aqueous formulation — i.e., the commercial Aloxi® IV product.

Patents asserted. The asserted claims in the consolidated trial were: '724 patent, claims 2 & 9 and '725 patent, claim 2 (pre-AIA; liquid palonosetron formulations at 0.05 mg/mL with EDTA, for "reducing emesis"); '424 patent, claim 6 (same family, EDTA limitation); and '219 patent (U.S. 8,598,219), claims 1, 2, 6 and 7 — "Liquid Pharmaceutical Formulations of Palonosetron," a single-use 5 mL unit dose of 0.25 mg palonosetron HCl with 0.005–1.0 mg/mL EDTA and 10–80 mg/mL mannitol, stable 24 months at room temperature. The '219 is the only AIA-era patent in the family (application filed May 23, 2013, claiming priority to a January 30, 2003 provisional), which is precisely why the AIA on-sale bar applied to it but not to its siblings. Two later-issued siblings, the '981 and '218 patents, were dismissed with prejudice by stipulation before trial (Dkt. 174, May 2014).

Procedural posture and venue. The member case in the prompt, Civ. A. No. 11‑5579 (MLC)(DEA), was filed September 23, 2011, asserting the '424 patent against Dr. Reddy's, Sandoz and Teva, and was consolidated into the lead action, Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, Ltd., No. 11‑3962 (MLC)(DEA), by order of Magistrate Judge Douglas E. Arpert on October 27, 2011 (Dkt. 68 in 11‑3962). The '219 entered the consolidated case through Civ. A. No. 13‑5815, filed September 30, 2013 and amended December 27, 2013 — so note that the '219 was not originally pleaded in 11‑5579, but became the lead case's most consequential patent. Presiding was U.S. District Judge Mary L. Cooper (D.N.J.), with Magistrate Judge Arpert handling discovery/consolidation. Sandoz was dismissed by consent on December 31, 2014 (Dkt. 247); the court construed the '219 preamble on April 22, 2015 (Dkt. 290); summary judgment motions were denied without prejudice on the eve of trial (Dkt. 307); an 11-day bench trial ran June 2–16, 2015 with closing arguments August 12, 2015; and during trial Teva and Dr. Reddy's stipulated that their 0.25 mg ANDA products met the '219 claims (Dkt. 335). Judge Cooper's opinion and final judgment issued November 13 and 16, 2015 (Dkts. 360–61), finding the '724, '725 and '424 patents valid and infringed as to both Teva strengths and the '219 valid and infringed as to the 0.25 mg product only. Dr. Reddy's settled and was dismissed October 16, 2015 (Dkt. 355); Teva appealed November 30, 2015 (Dkt. 365). Venue in D.N.J. was natural and essentially uncontested: the generics' U.S. subsidiaries (including Dr. Reddy's Laboratories, Inc.) are New Jersey corporations, Helsinn's U.S. affiliate is New Jersey-based, and D.N.J.'s Local Patent Rules supply a predictable Markman-to-trial track — the same reasons D.N.J. is a habitual forum for ANDA litigation. Related Helsinn suits against later filers (Accord/Intas, Mylan, Cipla, Aurobindo, Bedford, Sagent, and 15+ ANDA sponsors in all) were spread across D.N.J. and D. Del.

Why the case is notable. The '219 patent produced one of the most consequential patent-law rulings of the decade. On May 1, 2017, a Federal Circuit panel (Dyk, Mayer, O'Malley) reversed Judge Cooper and held the '219 claims invalid under the AIA on-sale bar, reasoning that a 2001 Helsinn–MGI license/supply agreement — disclosed in an 8‑K but with dosage details redacted — was a commercial offer for sale roughly two years before the January 2003 priority filing, and that the AIA's new "or otherwise available to the public" catchall did not narrow the reenacted "on sale" term: 855 F.3d 1356 (Fed. Cir. 2017). The Supreme Court affirmed unanimously on January 22, 2019 in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. ___, 139 S. Ct. 628 (Thomas, J.), holding that "an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art under § 102(a)" — a rule that now governs secret/confidential sales across all technologies and forced USPTO examination-guidance revisions. Commercially, the ruling collapsed a patent wall that Eisai had publicly said protected Aloxi® into mid‑2024 (formulation patents plus pediatric exclusivity); Teva launched generic palonosetron at risk on March 23, 2018 (while the appeal was pending, after Helsinn was denied a launch injunction), with Dr. Reddy's following March 26 and Sandoz April 2, 2018 — a stark illustration of how a single § 102 ruling can convert a settlement-protected franchise (Helsinn's Sandoz and Dr. Reddy's deals barred generic entry before September 30, 2018) into an immediate multi-source generic market. It also illustrates the IPR gap: because the on-sale bar is not an IPR-available ground, the AIA-era Helsinn patents were challenged via PGR (e.g., Dr. Reddy's PGR2016‑00008 on the '942 patent) rather than IPR, a strategic wrinkle frequently cited in the PTAB literature.

Sourcing caveats. The docket entries, dates and holdings above are grounded in the court's November 13, 2015 memorandum opinion (Dkt. 360, available via CourtListener/PACER), the consolidation order (Dkt. 68), the May 2014 consolidation/dismissal stipulation (Dkt. 174), the Federal Circuit opinion at 855 F.3d 1356, and the Supreme Court's opinion in No. 17‑1229. Two items I could not fully verify in this pass: (1) the precise post-Helsinn remand order/entry of judgment in D.N.J. after the Supreme Court's affirmance, and (2) exact annual U.S. Aloxi® revenue figures (Eisai books them; I did not confirm a specific dollar amount, so I have avoided one). The May 2018 at-risk launch dates come from a party brief filed in a related D.N.J. case (Helsinn v. Sagent, No. 16‑173), not from a court finding.

I'll research this case across the docket, court opinions, and PTAB records.

Confirmed: 3:11-cv-05579 is the Dr. Reddy's/Sandoz/Teva Aloxi ANDA case, consolidated into lead No. 3:11-cv-03962. Now let me dig into the trial, PTAB proceedings, and post-appeal history.

Let me get the Federal Circuit opinion details, the remand outcome, and check for any PGR/IPR on the '219 patent itself.

Bottom line

Plaintiffs in No. 3:11‑cv‑05579 are Helsinn Healthcare S.A. (Switzerland) and Roche Palo Alto LLC (Delaware, Palo Alto, CA). The case was a companion Hatch‑Waxman/ANDA suit against Dr. Reddy's, Sandoz, and Teva asserting U.S. 7,960,424, filed 9/23/2011 and consolidated on 10/27/2011 into the lead case, No. 3:11‑cv‑03962 (MLC)(DEA) (Dkt. 68, joint request and consolidation order). The plaintiff side used one consistent, three‑firm team across all of the Aloxi cases: Saul Ewing LLP (New Jersey local counsel), Paul Hastings LLP (New York, national/lead patent counsel), and Loeb & Loeb LLP (New York, of counsel).

⚠️ Two accuracy flags before the roster:

1. No. 11‑5579 did not itself assert the '219 patent. That complaint pleaded infringement of the '424 patent only. U.S. 8,598,219 issued 12/3/2013 and was asserted in No. 3:13‑cv‑05815, which was later consolidated into 11‑3962. So "counsel for plaintiffs in this case" and "counsel on the '219 patent" are the same team, but the '219 claims entered through the consolidated 2013 action, not the 2011 complaint.
2. I could not pull the 11‑5579 docket sheet's own appearance entries (it is not independently available on the free sources I reached; its papers were re‑maintained in 11‑3962 per the consolidation order). The names below are taken from the caption/signature blocks of the 11‑5579 complaint and the corresponding plaintiffs' filings in the consolidated lead case — i.e., attorneys who actually appeared, not inference.

---

Counsel of record for Helsinn Healthcare S.A. and Roche Palo Alto LLC

Local counsel (New Jersey) — Saul Ewing LLP, Newark

Source examples: 11‑5579 complaint signature block ("Charles M. Lizza, William C. Baton, SAUL EWING LLP … Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC"); Civ. A. No. 15‑7378, D.I. 53 ("This firm, together with Paul Hastings LLP and Loeb & Loeb LLP, represents plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC"). https://www.docketalarm.com/cases/New_Jersey_District_Court/3--15-cv-07378/HELSINN_HEALTHCARE_S.A._et_al_v._FRESENIUS_KABI_USA_LLC_et_al/docs/53.pdf

National / lead patent counsel — Paul Hastings LLP, New York ("Of Counsel" on the docket papers)

Source: 11‑5579 complaint caption block and Civ. A. No. 13‑5815 filings in the consolidated lead case, e.g. https://storage.courtlistener.com/recap/gov.uscourts.njd.[261662](/patent/261662).178.0.pdf

Of counsel — Loeb & Loeb LLP, New York

Appellate counsel (not district‑court counsel of record, but the same client)

• Kannon K. Shanmugam (counsel of record), with David M. Krinsky, Amy Mason Saharia, A. Joshua Podoll, Kathryn S. Kayali, Williams & Connolly LLP, Washington, D.C.; plus Stephen B. Kinnaird and Anand B. Patel, Paul Hastings LLP, Washington, D.C., and Charles M. Lizza, Saul Ewing, on the cert‑stage and stay filings in Helsinn Healthcare S.A. v. Teva, No. 17‑1229. https://www.supremecourt.gov/DocketPDF/17/17-1229/48436/20180529110656868_Helsinn%20cert%20reply.pdf

---

What is and isn't confirmed

• Confirmed by primary documents: the four‑attorney Loeb/Paul Hastings/Saul Ewing structure of plaintiffs' defense team, the individual names in the caption blocks, firm addresses, and Lizza's role as the New Jersey signatory. The caption block on the 11‑5579 complaint reads: Charles M. Lizza and William C. Baton (Saul Ewing) as "Attorneys for Plaintiffs," then "Of Counsel: Joseph M. O'Malley, Jr., Bruce M. Wexler, Eric W. Dittmann, David M. Conca, Gary Ji, Angela C. Ni, Paul Hastings LLP."
• Not verified: (a) the 11‑5579 docket's separate pro hac vice admission orders for the Paul Hastings lawyers (I saw the analogous pro hac vice practice in the related case — e.g., Teva's counsel admitted p.h.v. in 11‑3962 — but did not locate Helsinn's); (b) any formal designation of "lead" vs. "of counsel" beyond the caption blocks; (c) Mark E. Waddell's precise allocation between Helsinn and Roche.
• No sealed‑counsel issue: nothing in the record I reviewed suggests plaintiffs' counsel was sealed or under a protective order; the sealing motions in the consolidated case (e.g., D.I. 178‑series, plaintiffs' L. Civ. R. 5.3 motion) went to merits exhibits, not appearances.
• In‑house counsel: I found no Helsinn or Roche in‑house attorney appearing of record in 11‑5579/11‑3962; Helsinn's participation appears to have been through outside counsel only. Do not assume an in‑house appearance without a docket entry.

A note on later developments you may want in the case summary

The '219 patent ultimately went to trial in the consolidated case; on 11/13/2015 Judge Cooper held the asserted claims valid but not infringed by Teva's 0.075 mg PONV product (No. 11‑3962, Dkt. 360), and the Federal Circuit reversed the on‑sale‑bar ruling as to the '219 patent in 2017, affirmed by the Supreme Court in 2019 — all with the O'Malley/Dittmann/Lizza team on the briefs.

I'll research the docket and counsel appearances for this member case and the consolidated lead action.

Good initial hit — the trial transcript gives live appearances. Now let me pull the docket-level counsel listings and Sandoz's representation.

Strong leads. Now let me confirm the per-party counsel listings and signature blocks.

Counsel of record for the defendants — Civ. A. No. 11‑5579 (MLC)(DEA), consolidated into 11‑3962

Methodology / scope note. Counsel here is drawn from three primary record sources rather than a live PACER pull: (1) the signature blocks on the May 29, 2014 so‑ordered stipulation in the lead case, Dkt. 174 in Helsinn v. Dr. Reddy's, No. 11‑3962 (CourtListener RECAP); (2) the June 15, 2015 bench‑trial transcript "APPEARANCES" block in 11‑3962 (also lodged as Ex. 1043 in IPR2015‑01550); and (3) a Helsinn/Dr. Reddy's deposition transcript (Spilker) filed as a PTAB exhibit, which carries the MoFo, Hill Wallack and Budd Larner captions. Because 11‑5579 was consolidated into 11‑3962 on October 27, 2011 (Dkt. 68), the defense teams appeared once for all defendants across both dockets; there was no separate 11‑5579-only defense team. I flag below where the record is thin.

1. Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.